267 Transarterial chemoembolisation vs embolisation for hepatocellular carcinoma. A comparative audit

2004 ◽  
Vol 40 ◽  
pp. 83
Author(s):  
R. Stigliano ◽  
F. Morisco ◽  
C.W. Chan ◽  
L. Cecilioni ◽  
G. Leandro ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolisation ◽  
Comparative Audit

scholarly journals Synchronous presentation of tuberculosis and hepatocellular carcinoma in a cirrhotic patient: a case report

2019 ◽  
Vol 50 (1) ◽  
pp. 71-74
Author(s):  
Dhruvin Shah ◽  
Ganesh P ◽  
Shanmuganathan S ◽  
AK Koushik
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Liver Disease ◽  
Case Reports ◽  
Disease Patient ◽  
Immunocompromised Patients ◽  
Liver Lesions ◽  
Transarterial Chemoembolisation ◽  
Common Opportunistic Infection ◽  
Abdominal Lymphadenopathy

Tuberculosis (TB) is a common opportunistic infection which may be reactivated in immunocompromised patients. The incidence of hepatocellular carcinoma (HCC) is on the rise with healthcare resulting in increased longevity of people. Reactivation of TB has been reported with liver-directed therapies for HCC like transarterial chemoembolisation (TACE) and transarterial radio-embolisation (TARE). However, the co-occurrence of both TB and HCC in the same patient without any such history is rarely found. Only three isolated case reports have been published previously. We report the case of an elderly hepatitis C virus-related chronic liver disease patient who developed two different nodular liver lesions with multiple intra-abdominal lymphadenopathy, one such nodule being confirmed as HCC and another as TB along with nodal TB.

scholarly journals Hepatocellular carcinoma with type II–III portal vein tumour thrombosis: treatment using transarterial chemoembolisation and microwave ablation

2021 ◽  
Vol 94 (1117) ◽  
pp. 20200415
Author(s):  
Wen Peng Zhao ◽  
Honglu Li ◽  
Jiang Guo ◽  
Liang Cai ◽  
Youjia Duan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Adverse Events ◽  
Portal Vein ◽  
Microwave Ablation ◽  
Type Ii ◽  
Time To Progression ◽  
Treatment Alternative ◽  
Transarterial Chemoembolisation ◽  
Grade 3

Objective: To evaluate the use of transarterial chemoembolisation (TACE) combined with microwave ablation (MWA) to treat patients with hepatocellular carcinoma (HCC) and type Ⅱ–Ⅲ portal vein tumour thrombosis (PVTT) intolerant to targeted drug (TG) therapy. Methods: A total of 18 patients with HCC and type Ⅱ–Ⅲ PVTT intolerant to TG were enrolled between June 2015 and December 2019, who were treated with TACE + MWA (MWA group). 24 patients were treated with TACE + TG (TG group; control cohort). Time to progression and overall survival (OS) were analysed along with the incidence of adverse events. Results: The median follow-up time was 19.0 months (9.0–32.0 months). The median OS was 17.0 months (8.3–29.3 months; MWA group) and 13.5 months (5.5–22.5 months; TG group) and was not significantly different. The 1- and 2 year OS was also comparable (MWA group: 66.7%, 44.4% vs Target group: 41.7%, 29.2%). Time to progression showed no distinct differences (MWA group: 11.5 months; TG group: 9.0 months) between the two groups. Moreover, the incidence of major Grade 3–4 adverse events in the MWA group (5.6%) was similar to those in the TG group (8.3%). Conclusion: TACE + MWA and TACE + TG were comparable in their safety and efficacy in patients with HCC, type Ⅱ–Ⅲ PVTT, and intolerance to TG. Advances in knowledge: TACE + MWA can be used as a palliative treatment alternative for TACE + TG in patients with HCC, type Ⅱ–Ⅲ PVTT, and intolerance to TG.

Sign in / Sign up

Export Citation Format

Share Document